An observational study in Preeclampsia Awarness, sponsored by Aya Magdy Mohamed Amin. Not yet recruiting. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Aya Magdy Mohamed Amin · Observational
Preeclampsia is a major pregnancy-related hypertensive disorder and a leading cause of maternal and perinatal morbidity and mortality worldwide, particularly in developing regions. Adequate maternal awareness of preeclampsia symptoms and risk factors is crucial for early detection and timely medical intervention.
Objectives: This study aims to assess the level of awareness regarding preeclampsia, its warning signs, and its associated risk factors among pregnant women attending the antenatal care (ANC) clinic at Sohag University Hospital, and to identify socio-demographic factors associated with their awareness levels.
916 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
This study's planned enrollment of 160 is close to the median of 165 across 397 observational studies indexed under Pre-Eclampsia.
Browse Pre-Eclampsia studies →This is the only study on the registry with Aya Magdy Mohamed Amin as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Sohag University Hospital at the Obstetric and Gynecology department including admitted inpatient and those attending outpatient clinic .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Incomplete questionnaire responses.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Questionnaire
Data will be collected by the researcher through personal interviews with the PE admitted inpatient at the Obstetric and Gynecology department and those attending outpatient clinic at Sohag University Hospital using standardized questionnaire.
Preeclampsia Knowledge score
Assessed using an investigator-administered, validated, close-ended questionnaire covering preeclampsia awareness, risk factors, signs/symptoms, and complications. Each correct response receives 1 point, while incorrect or "don't know" responses receive 0 points. Scores are expressed as percentages and categorized into adequate knowledge (≥60%) and inadequate knowledge (\<60%).
Time frame: Baseline (at admission to the department or attendance at the outpatient clinic)
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Sep 2026; primary completion for Mar 2027, 6 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.